Subclinical hyperthyroidism is a common biochemical finding, characterized by low levels of serum TSH but normal serum T4 and T3levels. Potential adverse consequences include increased risk of atrial fibrillation and death from vascular diseases. Whether the evidence for harm associated with subclinical hyperthyroidism is sufficient to drive the need for treatment is discussed.